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Abstract
Identifying disease genes is crucial to the understanding of disease pathogenesis, and to the improvement of disease
diagnosis and treatment. In recent years, many researchers have proposed approaches to prioritize candidate genes by
considering the relationship of candidate genes and existing known disease genes, reflected in other data sources. In this
paper, we propose an expandable framework for gene prioritization that can integrate multiple heterogeneous data sources
by taking advantage of a unified graphic representation. Gene-gene relationships and gene-disease relationships are then
defined based on the overall topology of each network using a diffusion kernel measure. These relationship measures are in
turn normalized to derive an overall measure across all networks, which is utilized to rank all candidate genes. Based on the
informativeness of available data sources with respect to each specific disease, we also propose an adaptive threshold score
to select a small subset of candidate genes for further validation studies. We performed large scale cross-validation analysis
on 110 disease families using three data sources. Results have shown that our approach consistently outperforms other two
state of the art programs. A case study using Parkinson disease (PD) has identified four candidate genes (UBB, SEPT5, GPR37
and TH) that ranked higher than our adaptive threshold, all of which are involved in the PD pathway. In particular, a very
recent study has observed a deletion of TH in a patient with PD, which supports the importance of the TH gene in PD
pathogenesis. A web tool has been implemented to assist scientists in their genetic studies.
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Introduction
Dissecting genetic architectures of human diseases is a
fundamental task in human genetics and has profound implica-
tions in biomedical research. However, great challenges exist
because many common diseases are caused by multiple disease
genes with small to moderate effects. Even diseases that show
Mendelian inheritance may involve multiple genes due to
heterogeneity. Gene-gene interactions, as well as gene-environ-
ment interactions, also play an important role in the development
of diseases. Classifications of diseases, which are mostly based on
observed phenotypes, may not necessarily reflect their underlying
mechanisms. In addition, researchers have increasingly realized
that there are many levels of controls along the paths from
genotypes to phenotypes, resulting in a weaker relationship
between genotypes and phenotypes [1] that may or may not be
captured using traditional linkage or association approaches.
Furthermore, linkage analysis usually can only identify chromo-
somal intervals that may contain up to hundreds of candidate
genes owning to the limited number of crossovers in sampled
families. Genome-wide association studies may also return many
regions that show moderate to high signals. Experimental
validations of so many candidate genes are usually beyond the
ability of individual researchers owning to prohibitively high costs,
both in terms of fund and time.
Another limitation of linkage or association studies is that their
results only partially reflect the relationship between genes and
traits on account of many reasons, such as small genetic effects,
limited sample sizes, and limitations of statistical approaches. On
the other hand, it is well understood that genes have to be
transcribed and then translated into proteins, and proteins and
other molecular entities have to function in a synchronized matter
in the form of biological networks/pathways to perform normal
functionalities or to cause pathological phenotypic changes. A
variety of technologies exist to measure the levels of many such
activities. Over the years, a vast amount of data from different
sources has been accumulated and stored in a huge number of
biological databases, many of which are publicly available. For a
particular disease, such as breast cancer, tissue gene expression
data might exist in some databases. Known disease genes and their
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interaction (PPI) databases. Researchers may have also collected
and constructed disease pathways based on previous studies. All
these different data sets both confirm and complement each other,
which helps researchers study the biological phenomenons from
different aspects and levels. However, the conventional paradigm
that aims to establish a direct relationship between genotypes and
diseases through linkage and association studies mostly ignores all
the intermediate processes and data associated with them.
To solve this dilemma, researchers recently have proposed
approaches to prioritize candidate genes by using information
from different data sources, such as sequence-based features [2,3],
functional annotation data [4,5], protein interaction data [6–9],
gene expression data [10], or a combination of multiple data
sources [11–14]. The general idea of all these approaches is to
rank candidate genes from linkage/association results according to
their relationships with some known disease genes, reflected in
these data sources. For many data sources, one has to measure the
relationships between candidate genes and disease genes directly.
For other data sources, such as PPI networks, one can either
choose to measure the gene-gene relationships locally, or measure
them globally. Ko ¨hler et al. [7] have shown that global measures
perform better than local measures for prioritizing disease genes
using PPI networks. A fundamental issue in studies using a single
data source is the potential bias of their results caused by the
incompleteness and noise of one particular data set. Intuitively,
multiple data sources tend to provide better signal-to-noise ratio,
and thus may improve prediction accuracy. ENDEAVOUR
[11,14] is a popular online gene prioritization tool that utilizes
multiple data sources. It first ranks each candidate gene according
to each individual data source using various metrics. The ranks
from all data sources are then combined by using order statistics to
obtain an overall rank. Though it might provide better results
compared to approaches using a single data source, it has its own
limitations. First, different metrics have to be derived for different
data sources. It is not a trivial task if users need to add some new
data sources that are not available from its web server. Second, for
some data sources, such as PPI networks, simple local measures
are used, which may provide inferior results as shown in [7]. In
addition, each data source has its own noise or systematic errors.
The ranks obtained by ENDEAVOUR from each individual data
source are likely to be affected by those errors. When combining
the ranks, such effects can hardly be evaluated or quantified.
In this paper, we propose a general framework (Figure 1) for
candidate gene prioritization that can utilize multiple data sources
by taking advantage of a unified graphic representation. Gene-
gene relationships and gene-disease relationships are then defined
for each network based on a global measure (i.e., a diffusion
kernel). These measures are in turn normalized to derive an
overall measure across all networks, which is used to rank all
candidate genes. For each candidate-disease gene pair, only the
most informative network will contribute to the final gene-disease
relationship. In this way, we can automatically minimize errors
from unreliable data sources. We performed large scale cross-
validation analysis on 110 disease families from the OMIM
database using three data sources, based on protein interactions,
gene expressions and pathway information. Results have shown
that our approach consistently outperforms other two state-of-the-
art programs (i.e., random walk with restart [7] and ENDEAV-
OUR [11,14]). We also confirmed that approaches based on
global measures outperform approaches using local measures, and
the performance of our approach improves with increase in the
number of data sources. We have also defined a measure to
quantify the informativeness of networks with respect to each
disease. Improved performance has been observed on more
informative diseases for all approaches. Based on the informative-
ness measure, we also propose an adaptive threshold score that can
be used to select a small subset of candidate genes for further
validation studies. Taking Parkinson disease (PD) as a case study,
we tested our approach by considering all 3,243 genes that are
shared by all three data sources. We identified four candidate
genes (UBB, SEPT5, GPR37 and TH) that ranked higher than
our adaptive threshold, all of which are involved in the PD
pathway. In particular, a very recent study [15] has observed a
deletion of TH in a patient with PD, which supports the
importance of the TH gene in PD pathogenesis. A web tool has
been implemented to assist scientists in their genetic studies, which
can be accessed at http://cbc.case.edu/dir.
Methods
Data
Data Representation. One practical difficulty in integrating
different data sources lies in the fact that different types of data are
represented in different ways that are not directly comparable. To
solve this problem, we consider each data source at a conceptual
level. Essentially, we view a data source as evidence supporting
relationships among genes. More specifically, for each gene pair, a
data source can either support (to a certain degree) or not support
the fact that these two genes have a relationship within the context
of the given data. This is apparent in terms of PPI networks. A
direct interaction between a pair of proteins either has been
observed or has not been observed yet. The relationships between
a candidate gene (encoding the corresponding protein) and all
other genes/proteins can be thus defined. Such information can
also be obtained from other data sources. For example, gene
expression data can be transformed into gene co-expression
networks by connecting genes with similar expression patterns. To
represent known knowledge from biological pathways, a simple
network can be built by connecting genes (or their products) that
coexist in any pathway. Co-existence networks can also be built
Figure 1. The proposed integrative framework.
doi:10.1371/journal.pone.0021137.g001
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each data source is encoded by a graph, where nodes represent
genes and edges (with possible weights) represent relationships
between genes. It is obvious that such a representation only
partially captures information from original data sources and
inevitably inherits incompleteness and noise from its original data.
However, information loss as well as noise can be assumed to be
independent for the different data sources. Our hypothesis is that,
when one observes strong evidences from multiple sources using
this graph representation, it implies a possible true signal that is
worth further investigation. In this work, we primarily focus on
three specific data sources, namely, PPI, gene co-expression and
pathway networks. Knowledge from mining the literature is not
considered directly because it is known that methods relying on
text mining may produce biased results [7].
Protein-Protein Interaction Data. The protein-protein
binding data used in this study were derived from the HyNet
yeast-two-hybrid database [16] and curated molecular interaction
databases including Reactome [17], BIND [18], MINT [19] and
HPRD [20]. Duplicated edges between the same pair of nodes
were combined and edges connecting a node to itself were deleted.
The final protein-protein interaction network contains 11,006
human genes that encode proteins in the network and 54,732
edges. This exact dataset has been used in other previous
biological studies [21,22].
Human Gene Expression Data. The human tissue
expression dataset was obtained from GNF’s SymAtlas web site
[23]. This dataset consists of 79 human tissues in duplicates,
measured using the Affymetrix U133A array that consists of
22,215 probe sets. All array measurements were processed and
normalized using the Affymetrix MAS5 algorithm. Pairwise
Pearson correlation coefficients were calculated and a pair of
genes were linked by an edge if their correlation coefficient is
greater than 0:5. The correlation coefficients were then assigned as
weights for edges. The final network consists of 12,700 genes and
10,013,679 edges among them.
Pathway Data. The pathway dataset was obtained from the
Kyoto Encyclopedia of Genes and Genomes (KEGG) [24]
pathway database, which is a collection of manually curated
biological pathways. For simplicity, an edge was constructed
between two genes (or gene products), if they coexist in any
pathway. The ‘‘pathway network’’ constructed this way consists of
5,305 nodes and 1,176,449 edges.
Known Disease-Gene Associations. OMIM [25] is a large
database about genes and disease phenotypes curated by domain
experts. We have extracted the disease-gene relationships using the
software BioMart [26]. In addition, Ko ¨hler et al. [7] have
investigated similarities among diseases based on the entries in
OMIM and classified those with similar or even indistinguishable
phenotypes into disease families. By doing so, the number of
disease genes per family will be much greater than the number of
genes per disease. We adopted this classification of diseases and
further updated the disease families with new information by
adding newly discovered disease genes since Ko ¨hler et al. ’s paper
was published. There are total 944 distinct genes from 110 disease
families. The largest family contains 44 genes whereas the smallest
one contains 3 genes. The average number of genes per family is
8.58.
Approach
Candidate Gene Ranking Using a Single Source. Once
the information from a data source is represented by a network,
the relationship between a candidate gene and a disease can be
measured by the relationship between the candidate gene and all
known disease genes. The basic assumption of the Guilt-by-
Association principle [27] is that genes that are ‘‘close’’ to each
other in a network are expected to perform similar functions, thus
genes that are closer to disease genes will be more likely to be
associated with the same disease, and they should be ranked
higher. This principle is largely true for many networks, such as
PPI networks, and has been validated by many previous studies.
To define the closeness of a pair of genes or one gene to a group of
genes in general, several distance/similarity measures have been
proposed by considering the topology (as well as edge weights
when possible) of a network, either locally (such as direct
neighbor(DN), shortest path(SP)) or globally (such as diffusion
kernel (DK) and random walk with restart (RWR)). All of these
measures have been used in previous studies (e.g., in [7]). For the
sake of completeness, we briefly introduce them here and show
how they can be used in gene ranking. We will compare the
performance of our proposed approach with these methods.
Let M denote the adjacency matrix of a given network. For an
unweighted network such as the PPI or the pathway network,
M(i,j)~1 if there is an edge between gene i and gene j, and
M(i,j)~0 otherwise. For a weighted network such as the co-
expression network, M(i,j) is the Pearson correlation coefficient of
the two genes i and j if their correlation is greater than 0:5, and
M(i,j)~0 otherwise. Let DN, SP and DK denote the pairwise
distance/similarity matrix for measures based on direct neighbor,
shortest path and diffusion kernel, respectively. The direct
neighbor distance DN(i,j) between two genes i and j is defined
as 1,i fM(i,j)w0, and z? otherwise. The shortest path distance
SP(i,j) between two genes i and j is defined as the length of a
shortest path between the two genes, which can be easily
calculated based on standard graph algorithms. The diffusion
kernel is defined as: DK~e{cL, where c is a tuning parameter
and L~D{M, D being a diagonal matrix with the diagonal
elements containing the node degrees. The diffusion kernel
represents a global similarity between nodes in a graph, with
higher values representing closer relationships. For nodes that are
not connected, their values will be 0. For a specific disease family
G with a set A of known disease genes, and for a candidate gene b
in a set B of candidate genes, the relationship between b and G is
represented by the average distance between b and all
known disease genes in A. For example, for the DN measure,
DN(b)~
1
jAj
X
a[A DN(b,a). Such a proximity score can then
be used to rank all the genes in B.
Different from the three measures defined above, the RWR
approach [7] directly defines the relationship of a gene with a
group of disease genes. It is described as an iterative walker’s
transition from its current node to a randomly selected neighbor
starting at a set of given seed nodes (disease genes). Formally, the
RWR is defined as: ptz1~(1{r)M
0
ptzrp0, where M
0
is the
column-normalized adjacency matrix M and pt is a vector where
the ith element holds the probability of being at node i at time step
t. The initial probability vector p0 is constructed such that equal
probabilities are assigned to the nodes in set A, with the sum of the
probabilities equal to 1. The parameter r represents the restart
probability. The proximity score of a candidate gene b[B is then
defined as the corresponding element in the steady-state
probability vector p?, which is usually approximated by pt when
jpt{pt{1j is smaller than a predefined threshold. K€ o ohler et al. [7]
compared the performance of these four measures in prioritizing
candidate genes using the PPI network. They showed that the two
global measures (RWR and DK), which incorporate all the
connectivity information in a network and have similar perfor-
mance, clearly outperformed the two local measures (DN and SP).
Gene Prioritization by Integration
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in integrating different data sources, even if they all have been
represented using networks, because the distances defined in
different networks may not be directly comparable. In this study,
we propose an importance measure that is defined based on the
relative strength of the distance between a pair of genes among all
pairwise distances within each network. On assuming different
networks are independent, these measures from different networks
can be directly compared with one another. Such a framework can
be applied to any measures that can define pairwise distances/
similarities, such as direct neighbor, shortest path and diffusion
kernel. However, it cannot be directly applied to the RWR [7].
Because global distance measures are much better in capturing the
overall relationships in a network, we mainly focus on the
framework in combination with the diffusion kernel approach.
More specifically, let M1,M2,...,Mm denote the adjacency
matrices derived from m different datasets, respectively. Let
DKl,l~1,2,...m denote their diffusion kernels. The importance
of the similarity between a gene pair i and j is defined as:
DKPCl(i,j)~
jf(s,t)jDKl(s,t)§DKl(i,j)gj
jf(s,t)jDKl(s,t)w0gj
,l~1,2,...,m:
The numerator measures the number of pairs that are closer than
the pair (i,j). The denominator counts the total number of
connected pairs. Intuitively, for each gene pair, its DKPC value is
equal to one minus the percentile of its original diffusion kernel
similarity among all connected pairs. Therefore, the value is
smaller (or more significant) when the two genes are more similar.
If gene i and gene j are not connected in network l,
DKPCl(i,j)~1. With this definition, all relationships between
pairs of genes are scaled between 0 and 1 for all networks and can
be compared across different networks. Based on this importance
score, we further define our final data integration rank (DIR) score
for each candidate gene b from B with respect to a specific disease
family G with a set A of known disease genes as:
DIR(b)~
P
a[A maxf{log(DKPCl(b,a)),1ƒlƒmg
jfa[Ajmaxf{log(DKPCl(b,a)),1ƒlƒmgw0gj
:
The numerator sums the evidence over all disease genes within the
disease family. And for each disease gene a[A, it chooses the most
informative network to use by taking the max. The denominator
just counts the number of disease genes that provide information
in the numerator (i.e., those that are connected to the candidate
gene). This score reflects the overall relationship between gene b
and all known disease genes in A. By taking the max instead of
average, it potentially yields better performance because when
some networks are incomplete, which happens frequently, the
average score is usually much lower. The {log is mainly for the
stability of the score. The normalization by dividing the number of
disease genes that provide information can further account for the
incompleteness of some networks.
Meta Score and Declaration of Positives. One can directly
use the DIR score defined above to select genes that might be
associated with diseases. The greater DIR(b) is, the more likely
gene b will be associated with the disease and it will have higher
rank. Conventionally, researchers select a fixed number of
candidate genes (so called top-k approach) to report prioritization
results for all disease families. However, different disease families
usually have different numbers of known disease genes. It may not
be appropriate to use a global threshold in such a case. Following
the idea proposed by Zhou et al. [28], we define and automatically
calculate a meta score QG for a specificdiseasefamily G witha setA
of known disease genes based on the relationships of all these known
disease genes in all networks. Let C2
jAj denote the binomial
coefficient with parameters jAj and 2. QG is defined as:
QG~
P
i=j[A maxf{log(DKPCl(i,j)),1ƒlƒmg
C2
jAj
:
Intuitively, the meta score QG measures the average ‘‘closeness’’ or
significance of all disease genes of this disease family from all the
networks. If a candidate gene is closer to the disease genes than the
disease genes are to themselves on average, this candidate gene is
more likely to be associated with the disease, too. This meta score
can be used as a threshold for declaring significant candidate genes.
In the Results section, we will discuss the use of QG and its variants
as ‘‘adaptive ranking thresholds’’ and evaluate their performance in
comparison with the top-k approach.
Informativeness of a Network
The informativeness of networks is different for different disease
families. Even though the networks are quite comprehensive, some
disease genes may not occur in a network at all, or may have
limited connections. Therefore, for some disease families, it is not
appropriate to use the data sources to prioritize genes if the
networks themselves do not contain enough information about
these disease families. To formally quantify the informativeness of
a network with respect to a disease family G, we define a measure
of informativeness Il
G of a network l for a disease family G with a
set A of disease genes as the average pairwise relationship between
known disease genes:
Il
G~
P
i=j[A ({log(DKPCl(i,j)))
C2
jAj
:
In our experiments below, in addition to the overall performance
using all disease families, we also perform evaluations by
separating the disease families according to their informativeness.
Validation Method and Evaluation Criteria
We evaluate the proposed method using the leave-one-out
cross-validation approach, which has been adopted by many
previous studies (e.g., [7]). Briefly, for each disease gene in each of
the 110 disease families, we obtain 100 genes located nearest to
this disease gene on the same chromosome and rank all of them
together with this disease gene according to the score defined
above. The process is repeated for all disease genes to obtain final
results. We use two measures to measure the performance of our
approach. First, for each run, the enrichment factor is defined as
50/(rank of the tested disease gene), which will be highest if the
tested gene ranks first. Second, we also use the measure of the
receiver operating characteristic (ROC) curve, which shows the
relation between the sensitivity (true positive) and the specificity
(true negative rate) by varying the threshold for declaring positives.
The area under the ROC curve (AUC), which provides an overall
measure of the performance, is used to compare different
approaches.
Results
We first constructed the gene co-expression network, the PPI
network and the pathway network as described earlier, and
calculated the DKPC scores for each of them as the knowledge
Gene Prioritization by Integration
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the performance of our proposed approach under different
scenarios and compared its performance with two existing
cutting-edge approaches, RWR [7] and ENDEAVOUR [11,14].
We first evaluated the performance of our measure and all the
three other measures (i.e., DN, SP, and RWR) on a single
network, followed by the experiments using different number of
networks. We then compared our results with those by
ENDEAVOUR using three similar networks. We also examined
the results by separating the disease families according to their
mechanisms and their informativeness. Lastly, as a test case, we
present our results on the Parkinson disease family. The approach
has been implemented as a web tool and can be accessed freely.
Performance Using All Disease Families
By using the leave-one-out cross-validation, we first compared
the performance of our algorithm on all of the updated 110 disease
families with several state of the art algorithms that utilize single as
well as multiple data sources. More specifically, we tested our
approach (DIR) on the three networks that we constructed. Results
from ENDEAVOUR were obtained from three comparable data
sources that were listed in their package (i.e., PPI from HPRD,
pathway from KEGG and the same expression data from Su et al.
[23]). We also included the three approaches (RWR, DN and SP)
as well as our own approach on the PPI network alone (denoted as
DIR-PPI). The PPI network was chosen in the study of
performance on a single network because it has higher coverage
and is more informative than the other two networks, and PPI
networks have been widely used in previous studies (e.g., [21,22]).
In our implementation, if the disease gene left out for testing is not
in any network, it was assigned a random rank between 1 and 101.
Figure 2A shows the ROC curves of all the approaches tested. The
AUC values are also listed (in parenthesis) for each method. It is
apparent that DIR has the best overall performance, with the AUC
around 80.0%. The two approaches DIR and ENDEAVOUR,
using multiple data sources outperform all the approaches using the
PPI network alone. This is consistent with the general belief that by
collectingmoreevidencesfromdifferentdatasources,theprediction
results can be improved. The significant improvements of DIR
compared to DIR-PPI, as well as to RWR, further illustrate the
value of integrating multiple data sources. Though DIR is only
slightly better than ENDEAVOUR in terms of the AUC values
(80.0%vs.78.5%),the totalnumberoftestedgenesthatwereranked
first by DIR is much greater than the number of first ranked genes
by ENDEAVOUR (330 vs. 243). Consequently, the enrichment
factor achieved by DIR is better than that of ENDEAVOUR (21.9
vs. 18.5). The flat area in the middle of the ROC curve generated by
ENDEAVOUR is due to the way it deals with missing information
(see supplemental materials of [11]). On a single network, the two
approaches incorporating the global topology (RWR and DIR-PPI)
outperform the two approaches using local measures (DN and SP).
RWR is slightly better than DIR-PPI, which is also consistent with
previous studies [7]. Therefore, we dropped the three approaches
using a single network (DIR-PPI, DN and SP) from further
comparisons.
In general, disease genes usually receive more attention and
usually have been studied more intensively after they were
discovered. This is reflected by the fact that normally the average
degree (i.e., the number of links) of disease genes in some networks
is much greater than the average degree of non-disease genes (e.g.,
15.5 vs 9.5 in the PPI network). To assess whether our method
critically relies on this degree bias, we randomly shuffled the
networks while keeping the degree of each node unchanged. We
performed the same leave-one-out experiment. Roughly speaking,
Figure 2. A: ROC curves of cross-validation results by different approaches. The suffix ‘‘-PPI’’ after each method indicates it uses the PPI network only.
B: The ROC curve of DIR using the re-wired networks.
doi:10.1371/journal.pone.0021137.g002
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diagonal of the coordinate plane, which illustrates that our results
were not driven by the underlying degree distribution. However,
the AUC based on re-wired networks is not 0.5, which suggests
some bias that may be due to other reasons. We suspect the density
of the expression and pathway networks might affect this result.
Figure 3. Robustness assessments of DIR and RWR for their parameters ranging from 0.1 to 0.9 (left), as well as DIR from 0.01 to
0.09 (right).
doi:10.1371/journal.pone.0021137.g003
Figure 4. Left: The average performance of the five approaches using 100 randomly selected control sets. Right: The performance of the approaches
using all genes in the PPI network as the control set.
doi:10.1371/journal.pone.0021137.g004
Gene Prioritization by Integration
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some user-defined parameters in their framework. We performed
robustness analysis of both approaches and the results presented
above were obtained using the parameters that achieved the best
performance for both approaches. More specifically, the RWR
method has a parameter r that indicates the restart probability.
We varied r from 0:1 to 0:9 at increments of 0:1. The best result
was obtained when r~0:7. Therefore, we fixed r at 0:7 in our
experiments. DIR has a parameter c. We tested c in the same
manner from 0:1 to 0:9. The best result was obtained when
c~0:1 (Figure 3A). We further tested the performance of DIR for
c from 0:01 to 0:09 at increments of 0:01 for all three networks
together and separately. No significant changes were observed
(Figure 3B). Overall, the performance was very robust to c.W e
selected c~0:04 in our experiments. When we performed the
analysis on each network individually here, only genes that were
in the network were considered. This was different from the
experiment using all networks, as well as the experiments using
single networks elsewhere, in which cases all genes in a defined
control set were considered and a random rank was assigned to a
gene not in a network. When ignoring missed genes, using the
pathway alone actually can achieve better results when c is small
(Figure 3B), which is consistent with the fact that tight/direct links
in the pathway network are much more important than indirect
links.
Performance Using Alternative Control Sets. In our
experiments, we selected the 100 closest genes for each disease
gene asitscontrolset.Inordertotestthe robustnessofourapproach
withrespect to the selection of control sets, we performed large scale
cross-validation experiments using two alternatives. In the first
experiment, for each disease gene, we randomly selected 100 genes
from the PPI network as the control set. We performed the leave-
one-out cross-validation and obtained the performance result of
each approach. We further repeated this procedure 100 times to
obtain the variance of the AUC values. Results show that the
variances of the AUC values of all approaches tested are very small
and our method consistently performs better than RWR and other
approaches based on local measures (Figure 4A). The average
performance of DIR using control sets from the PPI network is not
as good as its performance using the closest neighboring genes. We
suspect this is mainly caused by the missing of some neighboring
genesinthesenetworks. Inthesecondexperiment,weexamined the
performance of these approaches using a genome-wide control set.
We took all the genes in the PPI network excluding those disease
genes as the control set. Once again, the leave-one-out cross-
validation was performed. Our method again consistently performs
better than RWR and other approaches based on local measures
(Figure 4B). Owing to its efficiency issue, ENDEAVOUR could not
finish the analysis on these two experiments in several days,
therefore we could not obtain its results.
Figure 5. Cross-validation results of three approaches on different disease categories. (A) ROC curves for monogenic diseases. (B) ROC
curves for polygenic diseases. (C) ROC curves for cancers. (D) AUC values on all disease families and on the three categories. (E) Percentage of first-
ranked disease genes for all diseases and the three categories. (F) Percentage of disease genes ranked in top-10 for all diseases and the three
categories.
doi:10.1371/journal.pone.0021137.g005
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On the basis of the mechanisms of diseases, Ko ¨hler et al.[ 7 ]
separated the 110 families into three categories: namely,
monogenic diseases, polygenic diseases, and cancers. The number
of families and the number of total disease genes in each of the
three categories are 85/615, 13/186, 12/143, for monogenic,
polygenic, and cancer diseases, respectively. We evaluated and
compared the three approaches (DIR, RWR and ENDEAV-
OUR) over the three categories of disease families separately.
DIR achieved the best overall performance and outperformed
both RWR and ENDEAVOUR in all three categories
(Figure 5A–D) in terms of the AUC values. Interestingly, all
three approaches have the best performance (i.e.,b e s tA U C
values) for the cancer disease families (Figure 5D). DIR
performed much better than RWR and ENDEAVOUR for the
polygenic disease families, while DIR and ENDEAVOUR
performed much better than RWR for the monogenic diseases.
In terms of the fraction of disease genes ranked in the first place
(Figure 5E), both DIR and RWR had about 35% of all tested
genes ranked first, while the fraction of first ranked genes by
ENDEAVOUR was much lower (about 25%). Similarly, when
separated into three categories, the fraction of genes ranked first
by ENDEAVOUR was much smaller than those of DIR and
RWR. ENDEAVOUR was able to catch up in terms the number
of genes ranked in the top ten list (Figure 5F), which explains why
it has better overall AUC than RWR. For different disease
categories, all approaches had better results for the monogenic
diseases when considering the first ranked genes. The highest
enrichment factor was achieved by DIR in the monogenic disease
families (23.0) and the lowest was ENDEAVOUR in the
polygenic diseases (13.8).
Informativeness of Networks and Performance Using
Different Numbers of Networks
We advocate the use of our approach for its capability of being
able to incorporate multiple data sources when prioritizing
candidate genes. To explore this further, we evaluated the
informativeness of the three networks with respect to the disease
families using the measure defined earlier, and examined the
performance of our approach using different combinations of data
sources. First of all, DIR has shown consistent improvements for
all the measures (the AUC values, the number of first-ranked
disease genes, the number of disease genes in the top-10 highest
ranked genes, and the average enrichment factors) when
increasing the number of data sources (Table 1), which again
verified our hypothesis that the approaches with multiple data
sources are preferred in gene prioritization. Second, among the
three networks, the gene co-expression network was the least
informative one, which is consistent with observations from
previous studies (e.g., [29]) that physical interaction data including
PPI usually provides stronger evidence for gene function
predictions compared to expression correlation. It seems counter
intuitive that the PPI was more informative than the pathway
network. This is mainly due to the difference in size/coverage of
the two networks. The number of genes in the pathway network is
significantly less than the number of genes in the PPI network.
Disease genes not in the pathway network received a random rank,
which contributed to the relative low performance of the pathway
network. When only considering genes that appear in the pathway
network, the pathway network is actually more informative (e.g.,
see Figure 3B). The combination of the PPI network and the
pathway network performs very well. Overall, the three networks
together show the best performance. Although the gene co-
expression network is not very informative as the PPI network and
the pathway network, including it increases the coverage of genes
and thus enables prioritizing candidate genes not captured by the
other two networks.
Table 1. Cross-validation results using different combinations
of data sources.
Data
Source EXP PWY PPI EXP+PWY EXP+PPI PPI+PWY ALL
AUC 58.3% 64.8% 72.5% 71.9% 76.5% 77.3% 80.0%
Ranked first 57 175 278 179 291 320 330
In top-10 199 339 466 391 513 520 561
Enrichment 6.7 13.5 18.7 13.7 19.9 21.1 21.9
EXP: co-expression network, PPI: protein-protein interaction network, PWY:
pathway network.
doi:10.1371/journal.pone.0021137.t001
Table 2. Three examples show improvements of DIR by integrating multiple data sources.
Disease Family/Informativeness Gene Name (Entrez ID) DIR RWR ENDEAVOUR
Generalized epilepsy with SCN2A(6326) 6 66 1
febrile seizures plus SCN1A(6323) 7 - 2
Exp PPI Pathway SCN1B(6324) 7 61 1
4.09 0.10 0.46 GABRG2(2566) 6 62 4
GABRD(2563) 1 50 7
Pituitary dwarfism LHX3(8022) 1 1 4
Exp PPI Pathway POU1F1(5449) 1 1 3
0.90 8.08 0.00 HESX1(8820) 1 1 1
PROP1(5626) 1 1 1
Aicardi-Goutieres syndrome RNASEH2A(10535) 1 29 23
Exp PPI Pathway RNASEH2B(79621) 2 72 16
2.29 0.31 4.10 RNASEH2C(84153) 1 - 72
The first column also lists the informativeness of each network contributing to each disease family.
doi:10.1371/journal.pone.0021137.t002
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when including more data sources. To further showcase the
improvement of prioritization on specific disease families by
integrating more data sources, we calculated the informativeness
of each network with respect to each disease family (i.e., Il
G). We
selected three disease families as an example to show the
improvement by approaches using multiple data sources
(Table 2). The informativeness of networks on all diseases can
be found in Dataset S1. In one example, the disease family
‘‘Generalized epilepsy with febrile seizures plus’’ obtains little
information from the PPI network. Therefore it was not surprising
that the RWR, which depends on the PPI network solely, could
not correctly predict disease genes in the cross-validation. In
contrast, the gene co-expression network provided sufficient
information about their connections. Consequently, the two
approaches DIR and ENDEAVOUR using the gene co-
expression network returned much better results. In another
example, the disease family ‘‘Pituitary dwarfism’’ has strong
information from the PPI network and has little information from
the other two networks. All three approaches performed well on
this family, which also illustrated that the performance of both
DIR and ENDEAVOUR were not weakened by including more
networks, even if some of them were not informative. In a last
example (Aicardi-Goutieres syndrome), both the gene co-expres-
sion network and the pathway network contributed to the success
of DIR in ranking the three genes. Relying on the PPI network
alone, RWR could not successfully rank these genes and missed
one gene (RNASEH2C) because it was not in the PPI network.
Performance on Informative Diseases
When using other data sources to prioritize candidate genes for
a disease, the effectiveness of any approach is essentially
determined by the coverage and information content in those
data sources, which represents the existing knowledge about
the disease. Based on the network informativeness (Il
G), we
ranked the disease families according to the maximum value of
the informativeness of the three networks. We chose a subset
of diseases that were more informative, defined as
maxfIl
G,1ƒlƒ3g§2:0 (which roughly corresponded to an
average DKPC score of 0.01 or lower). There was a total of 66
such families, consisting of 490 disease genes, and the top 15
families are listed in Figure 6A. The list of all disease families can
be found in Dataset S1. We summarize the cross-validation
experiment results of the three approaches again but using only
this set of 66 families (Figure 6B). Apparently, the performance of
all three approaches improved dramatically. For example, the
AUC values increased significantly: from 80:0% to 91:4% for DIR,
74:9% to 84:3% for RWR, and 78:5% to 88:4% for ENDEAV-
OUR. This suggests that with more information available,
network-based approaches can make better prioritization. Re-
searchers can always first evaluate the informativeness of the
networks with respect to their own diseases before applying any in
silico gene prioritization approaches.
Performance Using an Adaptive Rank Threshold
After obtaining a ranked list of all candidate genes, one needs to
define a rank threshold to declare disease susceptibility genes for
further studies. Ideally, such a threshold should be able to capture
the true disease genes while keeping the number of non-disease
related genes as small as possible. In practice, one has to balance
between the True Positive Rate (TPR) and the False Positive Rate
(FPR). To increase the TPR, one may always increase the FPR. A
straightforward method to declare positives is the Top-k criterion
(e.g., k~1 or 10) that declares all the top k best ranked candidate
genes as disease susceptibility genes. Our framework can naturally
utilize the meta score Q (i.e., QG for disease G) as the selection
criterion. The Q score reflects the relationship between known
disease genes. Our hypothesis is that the relationship between a
disease susceptibility gene and known disease genes should be
similar to the relationship among known disease genes themselves.
Our approach ranks candidate genes together with known disease
genes as well as with the meta score Q. If a candidate gene is
ranked better than Q, it is likely to be a true disease gene given that
Figure 6. A: A partial list of disease families that are most informative. B: Cross-validation results excluding disease families with
maxfIl
G,1ƒlƒ3gv2:0.
doi:10.1371/journal.pone.0021137.g006
Table 3. True Positive Rate and False Positive Rate using
different criteria.
Criterion Top-1 Q+1Q +1OR10 Top-10
True Positive Rate 54.0% 68.8% 68.8% 81.6%
False Positive Rate 0.46% 3.64% 2.49% 9.18%
doi:10.1371/journal.pone.0021137.t003
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is ranked better than Q, we declare the first ranked candidate gene
as the disease susceptibility gene. We call such a criterion the
‘‘Q+1’’ rule. In some cases, the relationship among existing disease
genes is not so strong, resulting in a low Q score. To avoid too
many false positives, we use the Q score only if it itself ranks in the
top-10 (excluding known disease genes). We call this one the
‘‘Q+1OR10’’ criterion. We have evaluated the Top-1, Top-10,
Q+1, and Q+1OR10 criteria on the 66 informative disease
families defined above. We calculated the TPR as the ratio of
successfully detected disease genes out of the total number of
disease genes. The non-disease genes that ranked higher than each
criterion are the false positives. The FPR is calculated as the
number of false positives divided by the total number of candidate
genes. Table 3 shows the TPR and FPR under each of the four
criteria. Although the Top-1 criterion has the smallest FPR, it also
suffers from the smallest TPR. On the contrary, the Top-10
criterion gives the highest TPR, but also the highest FPR. Our
criteria Q+1 and Q+1OR10 lie in between the two. In particular,
the performance of Q+1OR10 is appealing. Compared to the
Top-1 criterion, it can actually increase the TPR by 14:8% while
only increasing the FPR by 2:03%.
A Case Study
We chose the disease family ‘‘Parkinson Disease’’ (PD) as a case
study to perform a large scale de novo test of our proposed
algorithm. Parkinson disease is one of the most common
neurodegenerative disorders. For the PD disease family, we have
used the same definition in Ko ¨hler et al. [7], which consists of
several forms of Parkinson diseases such as, PARK, PARK1,
PARK2 (See Table 4 for details). The disease family has 8 known
disease genes and the cross-validation experiment ranked seven of
them at the first place and one of them (LRRK2) at the second
place. To identify some potential new PD disease genes, we
constructed the candidate gene set by including all 3,243 genes
that have appeared in all three networks. We ranked the candidate
genes together with the known disease genes and used the Q-score
to declare positives. Taking all 3,243 genes together, the Q-score
ranked number 9, and 4 disease genes and 4 candidate genes had
higher scores than Q (Figure 7). The four candidate genes are
ubiquitin B (UBB), septin 5 (SEPT5), G protein-coupled receptor
37 (GPR37) and Tyrosine hydroxylase (TH), all of which have
been involved in the Parkinson disease pathway (Figure 8). UBB
encodes ubiquitin, one of the most conserved proteins known.
Ubiquitin is required for ATP-dependent, nonlysosomal intracel-
lular protein degradation of abnormal proteins. Aberrant forms of
this protein have been noticed in patients with Alzheimer and
Huntington diseases [30], but not PD, though all three diseases
share a common feature in the accumulation of insoluble protein
deposits. SEPT5 is a member of the septin gene family of
Table 4. Disease genes from the Parkinson disease family and
related disorders.
Genes (OMIM ID) Disorder (OMIM ID)
SNCA (168601) Parkinson disease , familial, type 1 (PARK1) (163890)
PARK2 (600116) Parkinson disease 2, AR, juvenile (PARK2) (602544)
UCHL1 (191342) Parkinson disease 5 (191342)
PINK1 (605909) Parkinson disease 6, AR, early-onset (608309)
PARK7 (602533) Parkinson disease, autosomal recessive, early-onset
(606324)
LRRK2 (607060) Parkinson disease 8 (609007)
HTRA2 (610297) Parkinson disease 13 (606441)
SNCAIP (603779) Parkinson disease (603779)
doi:10.1371/journal.pone.0021137.t004
Figure 7. In the case study of the PD disease family, four candidate genes (in read) and four disease genes (in green) ranked higher
than the Q score (in blue), all of which are ordered according to their DIR values.
doi:10.1371/journal.pone.0021137.g007
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pathway (Figure 8). GPR37 is a substrate of parkin (PARK2), and
its insoluble aggregates accumulate in brain tissue samples of
Parkinson’s disease patients [31] (shown as PaelR in Figure 8). The
protein encoded by TH is involved in the conversion of tyrosine to
dopamine. It is the rate-limiting enzyme in the synthesis of
catecholamines, hence plays a key role in the physiology of
adrenergic neurons. Mutations in this gene have been associated
with autosomal recessive Segawa syndrome. Missense mutation in
both alleles of the TH gene is known to cause dopamine-related
phenotypes, including dystonia and infantile Parkinsonism. Most
recently, a study has found a rare novel deletion of the entire TH
gene in an adult with PD [15]. The result from this study had not
been entered into the OMIM database. This clearly shows the
value of our in silico prioritization approach, and the top ranked
genes returned by our approach should receive more attentions in
follow-up or validation studies. We have also tested RWR and
ENDEAVOUR on the same data set. All the four genes reported
by DIR are in the top 10 list of ENDEAVOUR, and five other
genes in the top 10 list of ENDEAVOUR are also ranked high by
DIR (i.e., in top 25 among more than 3000 candidates). The other
gene, ALS2, ranked number 2 by ENDEAVOUR, is not in the
top 100 by DIR. Literature search reveals that ALS2-related
disorders include Autosomal Recessive Juvenile Amyotrophic
Lateral Sclerosis, Infantile-Onset Ascending Hereditary Spastic
Paralysis and Juvenile Primary Lateral Sclerosis, but not PK.
Results from RWR are quite different from DIR and ENDEAV-
OUR, which is not surprising given that RWR has only utilized
the PPI network. The top 100 genes from each method can be
found in the supplemental Dataset S2.
Discussion
In this paper, we have proposed a candidate gene prioritization
approach that can integrate multiple data sources by taking
advantage of a unified graphic representation of information. Our
results have shown that based on a single network, both our
approach and the RWR approach have better performance than
Figure 8. The PD pathway obtained from the KEGG pathway database.
doi:10.1371/journal.pone.0021137.g008
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consistent with observations made by previous studies. Our
experiments have also shown that by integrating multiple sources,
DIR significantly outperformed all approaches relying on single
sources. Consistent improvements have been observed for DIR
when increasing the number of data sources from one to three.
Using three data sources and large scale cross-validations, we have
shown that the proposed approach outperforms two cutting-edge
methods. In terms of the AUC values, the improvement of DIR
over RWR is more impressive than the improvement of DIR over
ENDEAVOUR. Actually, in both cases, the improvements should
be statistically significant. Though one cannot directly estimate the
errors for these experiments, robustness analysis using different
control sets have shown that the estimated standard error of DIR
is very small (0.0026, Figure 4A), almost an order of magnitude
smaller than the performance difference. Furthermore, the
fraction of first ranked genes by DIR is much greater than the
fraction by ENDEAVOUR. The improvement of DIR over RWR
can be attributable to the inclusion of more data sources.
Comparing to ENDEAVOUR, in which case it first ranks a gene
based on an individual data source, the definition of the DIR
score, which utilizes only the most informative network for each
individual disease gene, may give us some advantage.
We have also presented an adaptive threshold to automatically
select a small subset of most promising candidate genes, which can
significantly improve the true positive rate while keeping the false
positive rate low. Our results have confirmed that global measures
are better than local measures in capturing gene-gene relation-
ships. Based on a global measure of gene-gene relationship, we
have proposed a measure of network informativeness, which can
be used to guide gene prioritization studies. We have shown that
the accuracy of our approach has been improved when using data
with higher quality. A case study on Parkinson disease has
illustrated the potential of the proposed approach.
The framework can be easily extended to include more data
sources, as long as there is an appropriate definition of gene
relationships for each data source. On the other hand, it is not
always easy to capture all the information from some original data
sources by using a graph representation. We will investigate the
inclusion of more data sources in our future work. For a specific
disease, the prediction result will be limited by existing knowledge
about the disease, including the number of known disease genes
and their relationships within the existing data sources. We have
used the concept of disease families in order to increase the
number of known disease genes in each family. Some recent
studies have considered relationships/similarities between diseas-
es/phenotypes [32] and have utilized phenotype similarities in
their gene prioritization approach [33–35]. We will investigate
approaches to incorporate phenotype similarities into our
framework.
Supporting Information
Dataset S1 The informativeness measures for all disease
families.
(XLSX)
Dataset S2 Top genes ranked by the three approaches on the
PD dataset.
(XLSX)
Acknowledgments
We thank Dr. R. Jiang from Tsinghua University for helpful discussion.
Author Contributions
Conceived and designed the experiments: JL YZ SKC. Performed the
experiments: YC WW. Analyzed the data: YC WW. Contributed
reagents/materials/analysis tools: YC WW RS. Wrote the paper: JL YC
WW YZ RCE.
References
1. Strohman R (2002) Maneuvering in the complex path from genotype to
phenotype. Science 296: 701–3.
2. Turner FS, Clutterbuck DR, Semple CA (2003) Pocus: mining genomic
sequence annotation to predict disease genes. Genome Biol 4: R75.
3. Adie EA, Adams RR, Evans KL, Porteous DJ, Pickard BS (2006) Suspects:
enabling fast and effective prioritization of positional candidates. Bioinformatics
22: 773–4.
4. Perez-Iratxeta C, Bork P, Andrade MA (2002) Association of genes to genetically
inherited diseases using data mining. Nat Genet 31: 316–9.
5. Freudenberg J, Propping P (2002) A similarity-based method for genome-wide
prediction of disease- relevant human genes. Bioinformatics 18 Suppl 2: S110–5.
6. Xu J, Li Y (2006) Discovering disease-genes by topological features in human
protein-protein interaction network. Bioinformatics 22: 2800–5.
7. Kohler S, Bauer S, Horn D, Robinson PN (2008) Walking the interactome for
prioritization of candidate disease genes. Am J Hum Genet 82: 949–58.
8. Oti M, Snel B, Huynen MA, Brunner HG (2006) Predicting disease genes using
protein-protein interactions. J Med Genet 43: 691–8.
9. Pattin KA, Moore JH (2008) Exploiting the proteome to improve the genome-
wide genetic analysis of epistasis in common human diseases. Hum Genet 124:
19–29.
10. Ala U, Piro RM, Grassi E, Damasco C, Silengo L, et al. (2008) Prediction of
human disease genes by human-mouse conserved coexpression analysis. PLoS
Comput Biol 4: e1000043.
11. Aerts S, Lambrechts D, Maity S, Van Loo P, Coessens B, et al. (2006) Gene
prioritization through genomic data fusion. Nat Biotechnol 24: 537–44.
12. Franke L, van Bakel H, Fokkens L, de Jong ED, Egmont-Petersen M, et al.
(2006) Reconstruction of a functional human gene network, with an application
for prioritizing positional candidate genes. Am J Hum Genet 78: 1011–25.
13. Chen J, Xu H, Aronow BJ, Jegga AG (2007) Improved human disease candidate
gene prioritization using mouse phenotype. BMC Bioinformatics 8: 392.
14. Tranchevent LC, Barriot R, Yu S, Van Vooren S, Van Loo P, et al. (2008)
Endeavour update: a web resource for gene prioritization in multiple species.
Nucleic Acids Res 36: W377–84.
15. Bademci G, Edwards TL, Torres AL, Scott WK, Zuchner S, et al. (2010) A rare
novel deletion of the tyrosine hydroxylase gene in parkinson disease. Hum Mutat
31: E1767–71.
16. http://www.ariadnegenomics.com/products/databases/prolexys-hynet/.
17. Vastrik I, D’Eustachio P, Schmidt E, Joshi-Tope G, Gopinath G, et al. (2007)
Reactome: a knowledge base of biologic pathways and processes. Genome Biol
8: R39.
18. Alfarano C, Andrade CE, Anthony K, Bahroos N, Bajec M, et al. (2005) The
biomolecular interaction network database and related tools 2005 update.
Nucleic Acids Res 33: D418–24.
19. Chatr-aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, et al.
(2007) Mint: the molecular interaction database. Nucleic Acids Res 35: D572–4.
20. Mishra GR, Suresh M, Kumaran K, Kannabiran N, Suresh S, et al. (2006)
Human protein reference database–2006 update. Nucleic Acids Res 34:
D411–4.
21. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, et al. (2008) Global
analysis of host-pathogen interactions that regulate early-stage hiv-1 replication.
Cell 135: 49–60.
22. Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, et al. (2011) Human host
factors required for influenza virus replication. Nature 463: 813–7.
23. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. (2004) A gene atlas of
the mouse and human protein-encoding transcriptomes. Proc Natl Acad
Sci U S A 101: 6062–7.
24. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From
genomics to chemical genomics: new developments in kegg. Nucleic Acids Res
34: D354–7.
25. Hamosh A, Scott AF, Amberger J, Bocchini C, Valle D, et al. (2002) Online
mendelian inheritance in man (omim), a knowledgebase of human genes and
genetic disorders. Nucleic Acids Res 30: 52–5.
26. Smedley D, Haider S, Ballester B, Holland R, London D, et al. (2009) Biomart–
biological queries made easy. BMC Genomics 10: 22.
27. Altshuler D, Daly M, Kruglyak L (2000) Guilt by association. Nat Genet 26:
135–7.
Gene Prioritization by Integration
PLoS ONE | www.plosone.org 12 June 2011 | Volume 6 | Issue 6 | e2113728. Zhou Y, Young JA, Santrosyan A, Chen K, Yan SF, et al. (2005) In silico gene
function prediction using ontology-based pattern identification. Bioinformatics
21: 1237–45.
29. Troyanskaya OG, Dolinski K, Owen AB, Altman RB, Botstein D (2003) A
bayesian framework for combining heterogeneous data sources for gene function
prediction (in saccharomyces cerevisiae). Proc Natl Acad Sci U S A 100:
8348–53.
30. Dennissen FJ, Kholod N, Steinbusch HW, Van Leeuwen FW (2010) Misframed
proteins and neu- rodegeneration: a novel view on alzheimer’s and parkinson’s
diseases. Neurodegener Dis 7: 76–9.
31. Marazziti D, Di Pietro C, Golini E, Mandillo S, Matteoni R, et al. (2009)
Induction of macroautophagy by overexpression of the parkinson’s disease-
associated gpr37 receptor. Faseb J 23: 1978–87.
32. van Driel MA, Bruggeman J, Vriend G, Brunner HG, Leunissen JA (2006) A
text-mining analysis of the human phenome. Eur J Hum Genet 14: 535–42.
33. Wu X, Jiang R, Zhang MQ, Li S (2008) Network-based global inference of
human disease genes. Mol Syst Biol 4: 189.
34. Vanunu O, Magger O, Ruppin E, Shlomi T, Sharan R (2010) Associating genes
and protein complexes with disease via network propagation. PLoS Comput Biol
6: e1000641.
35. Li Y, Patra JC (2010) Genome-wide inferring gene-phenotype relationship by
walking on the heterogeneous network. Bioinformatics 26: 1219–24.
Gene Prioritization by Integration
PLoS ONE | www.plosone.org 13 June 2011 | Volume 6 | Issue 6 | e21137